Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease.

Abstract:

BACKGROUND:In order to increase treatment choices for patients with Parkinson disease (PD), we performed a retrospective assessment of adverse events associated with a novel once-daily extended-release (ER) formulation versus the standard immediate-release (IR) of the nonergolinic dopamine agonist, pramipexole. METHODS:The PubMed and Embase databases, as well as the foreign language medical information resource retrieval platform were searched from 2007 to 2017. The relative risks (RR) of various adverse events with 95% confidence intervals (95% CIs) were generated. The Modified Jadad score (MJs) was used to assess the quality of individual studies. Funnel plots were used to evaluate publication bias. RESULTS:Three randomized controlled trials involving 1021 patients were included in this meta-analysis. We evaluated common adverse events associated with pramipexole in the gastrointestinal and nervous systems. These included the typical gastrointestinal symptom of nausea (RR = 0.96, 95% CI: 0.72-1.28; P = .80 > .05) and nervous system symptoms of somnolence (RR = 1.16, 95% CI: 0.95-1.43; P = .14 > .05), dizziness (RR = 1.11, 95% CI: 0.80-1.54; P = .54 > .05), and dyskinesia (RR = 0.87, 95% CI: 0.47-1.60; P = .66 > .05). CONCLUSION:Patients with PD treated with 2 different pramipexole formulations (ER and IR) had similar incidences of common adverse events.

journal_name

Medicine (Baltimore)

journal_title

Medicine

authors

Shen Z,Kong D

doi

10.1097/MD.0000000000011316

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

e11316

issue

34

eissn

0025-7974

issn

1536-5964

pii

00005792-201808240-00002

journal_volume

97

pub_type

杂志文章,meta分析

相关文献

MEDICINE文献大全